Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis-Reference-Cited by-同舟云学术

Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis

Published:2022-09-15 Issue:1 Volume:76 Page:148-151
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Donlan Alexandra N¹,Mallawaarachchi Indika²,Sasson Jennifer M¹,Preissner Robert³,Loomba Johanna J⁴,Petri William A¹⁵^ORCID

Affiliation:

1. Division of Infectious Diseases and International Health, University of Virginia School of Medicine , Charlottesville, Virginia , USA

2. Department of Public Health Sciences, University of Virginia School of Medicine , Charlottesville, Virginia , USA

3. Science-IT and Institute of Physiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Berlin , Germany

4. Integrated Translational Health Research Institute of Virginia (iTHRIV) , Charlottesville, Virginia , USA

5. Department of Pathology, University of Virginia School of Medicine , Charlottesville, Virginia , USA

Abstract

Abstract We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.

Funder

Manning Family Foundation

Ivy Foundation

Henske Family

NIH

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac745/46538797/ciac745.pdf

Reference12 articles.